Top Medical Stocks to Buy for Growth & Performance

Core Insights - The medical sector is gaining attention as investors seek defensive investments, particularly in health-related services [1] - The Zacks Strong Buy list currently includes 30 medical stocks, with Halozyme Therapeutics (HALO) and Neurocrine Biosciences (NBIX) being recent additions, both showing significant price performance over the past year [2][11] Company Performance - Neurocrine Biosciences is projected to see total sales growth of over 15% in FY24 and FY25, with estimates exceeding $2 billion, and EPS expected to increase by 71% in 2024 to $4.22 [8] - Halozyme Therapeutics is expected to have a 41% increase in EPS this year to $3.90, with FY25 EPS projected to rise by another 23% [12] - Haemonetics has shown a 30% increase over the last two years and a 141% gain over the past decade, with expectations of double-digit EPS growth in FY25 and FY26 [13] Valuation Metrics - Halozyme is trading at a forward earnings multiple of 13.5X, while Haemonetics is at 18.4X, which is below its decade-long high of 53.8X [12][13] - The medical sector is characterized by strong growth potential and favorable valuations, making it an attractive area for investment [10]